Literature DB >> 25387053

Hepatitis C virus-associated cancer.

Ming V Lin1, Lindsay Y King, Raymond T Chung.   

Abstract

Hepatitis C virus (HCV) is one of the major etiologic agents of liver cancer. HCV is an RNA virus that, unlike hepatitis B virus, is unable to integrate into the host genome. Through complex interactions between viral and host proteins that induce host responses and promote inflammation, fibrosis, and ultimately cirrhosis, HCV infection can result in the development of hepatocellular carcinoma (HCC). The HCV oncogenic process involves genetic and epigenetic alterations and oncogenic effects mediated by viral proteins in the activation of cellular oncogenes, inactivation of tumor-suppressor genes, and dysregulation of multiple signal-transduction pathways. Advances in genetics and gene expression profiling have enhanced our current understanding of the pathways involved in HCV-associated liver cancer development. In this review, we summarize the current understanding of mechanisms of hepatocarcinogenesis induced by HCV infection.

Entities:  

Keywords:  cancer; cirrhosis; hepatocellular carcinoma; liver

Mesh:

Year:  2014        PMID: 25387053     DOI: 10.1146/annurev-pathol-012414-040323

Source DB:  PubMed          Journal:  Annu Rev Pathol        ISSN: 1553-4006            Impact factor:   23.472


  34 in total

Review 1.  Diagnosis and treatment of hepatocellular carcinoma: An update.

Authors:  Javier Tejeda-Maldonado; Ignacio García-Juárez; Jonathan Aguirre-Valadez; Adrián González-Aguirre; Mario Vilatobá-Chapa; Alejandra Armengol-Alonso; Francisco Escobar-Penagos; Aldo Torre; Juan Francisco Sánchez-Ávila; Diego Luis Carrillo-Pérez
Journal:  World J Hepatol       Date:  2015-03-27

Review 2.  T Lymphocytes as Measurable Targets of Protection and Vaccination Against Viral Disorders.

Authors:  Anne Monette; Andrew J Mouland
Journal:  Int Rev Cell Mol Biol       Date:  2018-10-24       Impact factor: 6.813

Review 3.  Impact of hepatitis C virus eradication on hepatocellular carcinogenesis.

Authors:  Darrick K Li; Raymond T Chung
Journal:  Cancer       Date:  2015-06-16       Impact factor: 6.860

4.  Hepatitis C Virus core+1/ARF Protein Modulates the Cyclin D1/pRb Pathway and Promotes Carcinogenesis.

Authors:  Savvina Moustafa; Ioannis Karakasiliotis; Penelope Mavromara
Journal:  J Virol       Date:  2018-04-13       Impact factor: 5.103

5.  Association between MicroRNA-373 and Long Noncoding RNA NORAD in Hepatitis C Virus-Infected Hepatocytes Impairs Wee1 Expression for Growth Promotion.

Authors:  Subhayan Sur; Reina Sasaki; Pradip Devhare; Robert Steele; Ranjit Ray; Ratna B Ray
Journal:  J Virol       Date:  2018-09-26       Impact factor: 5.103

Review 6.  Hepatitis C Virus Manipulates Humans as its Favorite Host for a Long-Term Relationship.

Authors:  Ratna B Ray; Ranjit Ray
Journal:  Hepatology       Date:  2019-02       Impact factor: 17.425

7.  The phosphatase PAC1 acts as a T cell suppressor and attenuates host antitumor immunity.

Authors:  Liang Liu; Yizhe Sun; Jia Song; Qi Yin; Guangze Zhang; Fang Qi; Zixi Hu; Zeliang Yang; Zhe Zhou; Ying Hu; Lianhai Zhang; Jiafu Ji; Xuyang Zhao; Yan Jin; Michael A McNutt; Yuxin Yin
Journal:  Nat Immunol       Date:  2020-01-13       Impact factor: 25.606

8.  The wound inflammatory response exacerbates growth of pre-neoplastic cells and progression to cancer.

Authors:  Nicole Antonio; Marie Louise Bønnelykke-Behrndtz; Laura Chloe Ward; John Collin; Ib Jarle Christensen; Torben Steiniche; Henrik Schmidt; Yi Feng; Paul Martin
Journal:  EMBO J       Date:  2015-07-01       Impact factor: 11.598

9.  Divergent viral presentation among human tumors and adjacent normal tissues.

Authors:  Song Cao; Michael C Wendl; Matthew A Wyczalkowski; Kristine Wylie; Kai Ye; Reyka Jayasinghe; Mingchao Xie; Song Wu; Beifang Niu; Robert Grubb; Kimberly J Johnson; Hiram Gay; Ken Chen; Janet S Rader; John F Dipersio; Feng Chen; Li Ding
Journal:  Sci Rep       Date:  2016-06-24       Impact factor: 4.379

Review 10.  Exploring Internal Ribosome Entry Sites as Therapeutic Targets.

Authors:  Anton A Komar; Maria Hatzoglou
Journal:  Front Oncol       Date:  2015-10-20       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.